DPC News

(Listen, Exclusive) “Changing lives with new advances in regenerative medicine …” Dr. Robert Kellar

 

Dr. Robert Kellar is the Chief Science Officer for Axolotl Biologix. He has over 17 years of experience in the development and regulatory approval of medical devices, cell-based products, and regenerative medicine and tissue-engineered technology. He has 30 peer-reviewed publications and 4 issued US patents. He received his PhD from the University of Arizona in 2001. Dr. Kellar currently serves on the Scientific Advisory Board for MyoStim, and is on the Faculty in the Center for Bioengineering Innovation (CBI), Biological Sciences and Mechanical Engineering at Northern Arizona University. Dr. Kellar has helped to co-found a number of companies including Development Engineering Sciences, a biomedical consulting firm, Flagship Biosciences, a digital pathology company, and Autogenesis Corporation, a wound healing company. He serves as an Advisory Board Member for Protein Genomics, a protein polymer medical device company, and the California Stock Exchange. Dr. Kellar’s previous roles include: VP of Research and Development at Histogen, Inc. in San Diego, CA, Product Specialist at W.L. Gore and Associates in Flagstaff, AZ, and Lead Scientist and Project Manager at Advanced Tissue Sciences, Inc. in La Jolla, CA.

EP 323 | “Changing lives with new advances in regenerative medicine …” Meet Dr. Robert Kellar

By Michael Tetreault, Editor-in-Chief, Concierge Medicine Today, Host, The DocPreneur Leadership Podcast

Today we sit down with Dr. Robert Kellar, Ph.D, Chief Science Officer for Axolotl Biologix and faculty in the Center for Bioengineering Innovation (CBI), Biological Sciences and Mechanical Engineering at Northern Arizona University.

Axolotl Biologix is focused on developing novel products that are safe and effective. We are dedicated to providing a level of quality and service to our clients that is a cut above the field. Axolotl is actively developing future products that will continue to foster regeneration and healing.  Interested in learning more about the science behind Axolotl products? Check out our Science & Research section for Peer-Reviewed Papers, White Papers and Posters.

RELATED EVIDENCE AND RESEARCH | PRECISION MEDICINE | BIO-TECH | FOR DOCTORS

Peer-Reviewed Papers

Characterization and Clinical Applications of Amniotic Membranes

Vo, A., Diller, R.B., Kellar, R.S.

Platelet-Rich Plasma and Amnion-Derived Fluid

Lee, E.T., Diller, R.B., Kellar, R.S.

Amnion-Derived Fluid and Amniotic Fluid

Bigbey, M., Lee,E., Diller, R.B., Kellar, R.S.

RELATED STORY

CMS Makes It Easier for Healthcare Providers to Choose Axolotl Biologix Products to Spur Wound and Tissue Regeneration

Background

Robert Kellar, Ph.D. is a highly respected biotechnology innovator focused on improving patients’ quality of life through advanced regenerative medicine technologies. He the Chief Science Officer for Axolotl Biologix and on the faculty in the Center for Bioengineering Innovation (CBI), Biological Sciences and Mechanical Engineering at Northern Arizona University. Dr. Kellar has over 17 years of experience developing medical devices, cell-based products, and regenerative medicine and tissue engineered technology. He has 121 scientific abstracts, 30 peer-reviewed publications, and 4 issued US patents.

Dr. Kellar currently serves on the Scientific Advisory Board for MyoStim, and has helped to co-found a number of companies including Development Engineering Sciences, a biomedical consulting firm, Flagship Biosciences, a digital pathology company, and Autogenesis Corporation, a wound healing company. He also serves as an Advisory Board Member for Protein Genomics, a protein polymer medical device company, and the California Stock Exchange.

Axolotl Biologix, Inc. is a Phoenix-based, innovative biotechnology leader in regenerative medicine. They develop and manufacture regenerative human cell and tissue medical technologies that disrupt traditional, more invasive, painful and expensive treatment protocols. www.axobio.com

 

What’s next at AxoBio?

We have a next generation set of products that we are excited about. We incorporated a technology called Tropoelastin, a precursor to elastin. You stop producing elastin at the age of twelve. By the age of seventy over half of it is gone and that is why your skin wrinkles, your blood pressure goes up, your tendons and ligaments have sports injuries; because you lose the elasticity and the stretchiness of your different tissues. We have a fluid that will be enhanced by the use of Tropoelastin, which is a water soluble version of elastin. Then we can print different scaffoldings, such as skin scaffoldings, heart patches and blood vessels that are perfect matches for the patient. Where we are using collagen and fiber in our Tropoelastin, then electrospinning scaffoldings which match the fiber diameter that is found within the native tissues; we basically make an identical scaffolding that your cells are already existing within.

RELATED STORY

Axolotl Biologix Launches New Axolotl Shot™ For Wound Care

Pre-Loaded Regenerative Medicine Syringe Saves Doctors Time and Money

Phoenix, AZ (Dec. 5, 2018) – Axolotl Biologix, an innovative biotechnology leader in regenerative medicine, is proud to announce the launch of Axolotl Shot™, an ambient temperature regenerative fluid preloaded into a syringe for ease of use by physicians.

Axoltol Biologix is the first to market a preloaded syringe containing a regenerative fluid that is manufactured using the proprietary BioSym™ process to yield growth factors and cytokines known to stimulate cellular growth and repair. It offers significant therapeutic benefits to help facilitate repair and regeneration of damaged cells and tissues.

“Our new Axolotl Biologix treatment option uses the latest advances in biotechnology to improve patient outcomes while making it more convenient for physicians,” said Dr. Robert Kellar, Chief Science Officer.  “The Axolotl Shot is preloaded in 1mL and 2mL volumes, terminally irradiated for use in surgical applications, and since it can be stored at room temperature there is no storage concerns or down time waiting for product to thaw.”

This new option benefits consumers because it can be applied during a same-day outpatient visit, helping patients avoid the costs, pain and downtime associated with surgery.

“Axolotl Biologix is excited to introduce the Axolotl Shot which has potential clinical benefits in a variety of applications that will help physicians, orthopods, and wound care specialists save time and money treating patients,” said Phillip Larson, President of Axolotl Biologix.

Axolotl Shot is a regenerative fluid derived from the amniotic components of the placenta to promote regeneration and repair of damaged or degenerated tissues. Donor tissue is recovered and processed aseptically in accordance with all FDA guidelines and quality assurance standards in a controlled environment.

About Axolotl Biologix:

Axolotl Biologix, Inc. is an innovative biotechnology leader in regenerative medicine through research, technology and clinical application. Axolotl Biologix is expanding the human body’s ability to regenerate by developing and manufacturing regenerative human cell and tissue medical technologies that are disrupting traditional, more invasive, painful and expensive treatment protocols. For more information, visit www.axobio.com

###

Axolotl Biologix CSO Recognized Among Arizona’s Top Healthcare Leaders

Chief Science Officer Selected For 2019 Researcher of the Year

Phoenix, AZ (May 22, 2019)Axolotl Biologix, an innovative biotechnology leader in regenerative medicine, is proud to announce its Chief Science Officer, Robert Kellar, Ph.D., has been recognized as one of Arizona’s top healthcare leaders. Arizona Business Magazine’s editorial board selected Kellar as one of 2019’s Healthcare Researchers of the Year.

The business magazine called Kellar a highly respected biotechnology innovator, listing his regenerative medicine technologies, Axolotl Shot and Axolotl DualGraft, as evidence of his valued contributions to the field. These technologies enable the body’s tissues and cells to repair and regenerate, giving patients new options to improve outcomes without the costs and discomforts of surgery.

“I am honored to be recognized along with this highly esteemed group of researchers who are dedicated to shaping the future of healthcare in Arizona,” said Kellar. “I have made it my life’s work to research and develop innovative therapeutic options that disrupt traditional treatments and I am grateful to Axolotl Biologix for giving me an incredible team that has accomplished so much, so quickly.”

Kellar has spent nearly 20-years developing, manufacturing, and commercializing medical devices and technologies both as a researcher and professor. He’s currently at Northern University Arizona serving as an Associate Professor in the Center for Bioengineering Innovation, Co-Director of the Bioengineering Ph.D. Program, Co-Director for the Imaging & Histology Core Facility (IHCF), and an adjunct faculty member in Mechanical Engineering.

Axolotl Biologix is a national leader in regenerative medicine with liquid and membrane allograft products to help promote repair and regeneration of damaged tissues. Kellar’s team also created Axolotl Ambient™, the first commercially available room temperature regenerative fluid product that is now available through federal agencies such as the Veterans Administration and Indian Health Services.

Arizona Business Magazine named Kellar among the five Healthcare Researchers of the Year in its May issue honoring 2019 Healthcare Leaders of the Year. The other honorees are Marc Jacofsky, Ph.D., Chief Science Officer for The CORE Institute, Akinlolu O. Ojo, M.D., Associate Vice President for Clinical Research and Global Health Initiatives at the University of Arizona Health Sciences, Sunil Sharma, M.D., Deputy Director of Clinical Sciences for Translational Genomics Research Institute and Kris Vijay, M.D., Medical Director for the Institute of Congestive Heart Failure at Abrazo Arizona Heart Hospital.

About Axolotl Biologix:

Axolotl Biologix, Inc. is an innovative biotechnology leader in regenerative medicine through research, technology and clinical application. Axolotl Biologix is expanding the human body’s ability to regenerate by developing and manufacturing regenerative human cell and tissue medical technologies that are disrupting traditional, more invasive, painful and expensive treatment protocols. For more information, visit www.axobio.com

###

Media Contact:

Josh Weiss

10 to 1 Public Relations

josh@10to1pr.com

480-789-0743

Laura Slawny

10 to 1 Public Relations

laura@10to1pr.com

480-868-9423

Categories: DPC News, Homepage Slider

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s